Elivaldogene Autotemcel
drugOn this page
Also known as Elivaldogen autotemcelLenti-D Drug substanceSkysona
Summary
Elivaldogene Autotemcel (CHEMBL4594333) is an approved gene (ATC A16AX21); indicated across 1 condition including adrenoleukodystrophy.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Gene
- ATC class: A16AX21
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4594333 |
| Name | Elivaldogene Autotemcel |
| Type | Gene |
| Max phase | 4 |
| ATC | A16AX21 |
Also known as: Elivaldogen autotemcel, Elivaldogene autotemcel, Lenti-D Drug substance, Skysona, ELIVALDOGENE AUTOTEMCEL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| adrenoleukodystrophy | 4 | MONDO:0018544 | Orphanet:43 |
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: adrenoleukodystrophy